RhoVac featured in international trade press
RhoVac AB ("RhoVac") was featured in the international trade press, April 24, as the well reputed industry-specific e-journal Scrip - Pharma Intelligence published an interview with CEO Anders Månsson.The well reputed industry-specific e-journal Scrip - Pharma Intelligence, interviewed CEO Anders Månsson about the company's ongoing clinical phase IIb study in prostate cancer, called BRaVac. In the interview, CEO Anders Månsson explains that RhoVac's RV001 treatment is "tissue agnostic", i.e. that the treatment is not limited to prostate cancer only, but that it could probably be developed